A bioactive peptide analogue for myxoma virus protein with a targeted cytotoxicity for human skin cancer in vitroReport as inadecuate

A bioactive peptide analogue for myxoma virus protein with a targeted cytotoxicity for human skin cancer in vitro - Download this document for free, or read online. Document in PDF available to download.

Journal of Biomedical Science

, 19:65

First Online: 17 July 2012Received: 11 May 2012Accepted: 17 July 2012DOI: 10.1186-1423-0127-19-65

Cite this article as: Almansour, N.M., Pirogova, E., Coloe, P.J. et al. J Biomed Sci 2012 19: 65. doi:10.1186-1423-0127-19-65


BackgroundCancer is an international health problem, and the search for effective treatments is still in progress. Peptide therapy is focused on the development of short peptides with strong tumoricidal activity and low toxicity. In this study, we investigated the efficacy of a myxoma virus peptide analogue RRM-MV as a candidate for skin cancer therapy. RRM-MV was designed using the Resonant Recognition Model RRM and its effect was examined on human skin cancer and normal human skin cells in vitro.

MethodsCell cultures were treated with various concentrations of the peptides at different incubation intervals. Cellular morphological changes apoptosis and necrosis were evaluated using confocal laser scanning microscopy. The cytotoxic effects of RRM-MV on human skin cancer and normal human skin cells were quantitatively determined by cytotoxicity and cell viability assays. The effect on human erythrocytes was also determined using quantitative hemolysis assay. DNA fragmentation assay was performed to detect early apoptotic events in treated cancer cells. Furthermore, to investigate the possible cell signalling pathway targeted by the peptides treatment, the levels of p-Akt expression in skin cancer and normal cells were detected by immunoblotting.

ResultsOur results indicate that RRM-MV has a dose-dependent toxic effect on cancer cells only up to 18 h. The immunoblotting results indicated that the RRM-MV slightly increased p-Akt expression in melanoma and carcinoma cells, but did not seem to affect p-Akt expression in normal skin cells.

ConclusionsRRM-MV targets and lethally harms cancer cells and leaves normal cells unharmed. It is able to reduce the cancer cell viability, disrupting the LDH activity in cancer cells and can significantly affect cancer progression. Further investigation into other cell signalling pathways is needed in the process leading to the in vivo testing of this peptide to prove its safety as a possible effective treatment for skin cancer.

KeywordsRRM-MV Myxoma virus Bioactive peptide Melanoma Carcinoma AbbreviationsCOLO-16Human squamous cell carcinoma cell line

DNADeoxyribonucleic acid

HDFNormal human dermal fibroblast cell line

HEMNormal human epidermal melanocytes cell line

LDHLactate dehydrogenase

MM96LHuman malignant melanoma cell line

MVMyxoma virus.

Electronic supplementary materialThe online version of this article doi:10.1186-1423-0127-19-65 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Author: Nahlah M Almansour - Elena Pirogova - Peter J Coloe - Irena Cosic - Taghrid S Istivan

Source: https://link.springer.com/

Related documents